Difference between revisions of "Quality"
Jump to navigation
Jump to search
m (→See also) |
(IHC classes) |
||
| Line 38: | Line 38: | ||
==Biopsy size== | ==Biopsy size== | ||
Very small tissue fragments are associated with a decreased diagnostic yield and an increased diagnostic uncertainty. | Very small tissue fragments are associated with a decreased diagnostic yield and an increased diagnostic uncertainty. | ||
==Immunohistochemistry== | |||
A paper by Torlakovic ''et al.''<ref name=pmid20154273>{{Cite journal | last1 = Torlakovic | first1 = EE. | last2 = Riddell | first2 = R. | last3 = Banerjee | first3 = D. | last4 = El-Zimaity | first4 = H. | last5 = Pilavdzic | first5 = D. | last6 = Dawe | first6 = P. | last7 = Magliocco | first7 = A. | last8 = Barnes | first8 = P. | last9 = Berendt | first9 = R. | title = Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. | journal = Am J Clin Pathol | volume = 133 | issue = 3 | pages = 354-65 | month = Mar | year = 2010 | doi = 10.1309/AJCPDYZ1XMF4HJWK | PMID = 20154273 }}</ref> divides IHC tests into: | |||
*''Class I'': | |||
**Adjunct to histomorphology. | |||
**Example: CD45, S-100. | |||
*''Class II'' - used directly for treatment decisions; it is considered independent of the other information in the pathology report. | |||
**ER, PR, HER2. | |||
==See also== | ==See also== | ||
Revision as of 01:50, 18 January 2012
Quality, in pathology, has got a lot of attention lately because there have been high profile screw-ups that lead to significant harm.[1]
Analysis
Quality issues are examined a number of different ways, e.g. root cause analysis, failure mode and effects analysis (FMEA).
A common way to break down error analysis is:
| Errors in pathology | |||||||||||||||||||||||||||||||||
| Pre-analytical errors | Analytical errors | Post-analytical errors | |||||||||||||||||||||||||||||||
Error reduction
Various strategies can be employed:[2]
- Training of staff - on error handling.
- Computer order entry.
- Avoid duplication fatigue.
- Quick correlation with several identifying features.
- Full name, sex, date of birth -- these all appear when one opens a case.
- Barcode use.
- Avoid transcription errors.
- Clinical information entry required.
- Allow correlation with test.
- The interpretation may differ if the history says "screening coloscopy" versus "large cecal mass, anemia and weight loss".
- Allow correlation with test.
Other strategies:
- Statistical process control.
Sources of error
- "Human error".
- Training.
- Work flow.
- Process gaps.
- Process control.
- Lack of redundancy.
Biopsy size
Very small tissue fragments are associated with a decreased diagnostic yield and an increased diagnostic uncertainty.
Immunohistochemistry
A paper by Torlakovic et al.[3] divides IHC tests into:
- Class I:
- Adjunct to histomorphology.
- Example: CD45, S-100.
- Class II - used directly for treatment decisions; it is considered independent of the other information in the pathology report.
- ER, PR, HER2.
See also
References
- ↑ URL: http://www.attorneygeneral.jus.gov.on.ca/inquiries/goudge/index.html. Accessed on: 1 March 2011.
- ↑ Fabbretti, G. (Jun 2010). "Risk management: correct patient and specimen identification in a surgical pathology laboratory. The experience of Infermi Hospital, Rimini, Italy.". Pathologica 102 (3): 96-101. PMID 21171512.
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.